1. Home
  2. Directory
  3. Utah
  4. Salt Lake City
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1639738545

ELIZABETH EVE POTTER
Prescription History 1639738545
Nurse Practitioner - Family in Salt Lake City, UT

NPI Status: Active since June 13, 2019

Contact Information

1160 E 3900 S STE 2000
SALT LAKE CITY, UT
ZIP 84124
Phone: (801) 266-3418
Fax: (801) 266-4174

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ELIZABETH EVE POTTER, an active Family specialist practicing in Salt Lake City, UT. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 212 documented patient claims. Among these therapy options, the most frequently utilized medication is Gabapentin, which accounts for 61 claims alone.

Medication Index

Baclofen

Generic Formulation: BaclofenSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 53
30-Day Fills 110.3
Days Supply 3,310
UT State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills44.0
Peer Average Days Supply1,212
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 60.6% higher than the standard regional baseline profile for UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,205.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.62

State Avg Cost Per Claim

$31.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission.

Therapeutic Applications

Baclofen is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury/disease). It works by helping to relax the muscles.

Dalfampridine Er

Generic Formulation: DalfampridineSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 23
30-Day Fills 27.0
Days Supply 810
UT State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply1,268
Conservative Utilization

This provider writes prescriptions for this formulation 32.4% less frequently than the standard regional baseline metric for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,271.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$272.66

State Avg Cost Per Claim

$465.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes.

Therapeutic Applications

Dalfampridine is used to improve walking in people with multiple sclerosis (MS). It is a potassium channel blocker. It is thought to work by improving nerve conduction.

Diazepam

Generic Formulation: DiazepamSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 11
UT State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills26.9
Peer Average Days Supply655
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.0% less volume than the regional standard for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$0.93

State Avg Cost Per Claim

$9.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.

Therapeutic Applications

This medication is used to treat episodes of increased seizures (such as cluster or breakthrough seizures) in people who are already taking medications to control their seizures. This product is only recommended for short-term treatment of seizure attacks. It is not for ongoing daily use to prevent seizures. Uncontrolled seizures can turn into serious (possibly fatal) seizures that do not stop (status epilepticus). This medication is not recommended for children younger than 6 months of age because of the risk of serious side effects. Diazepam works by calming the brain and nerves. It belongs to a class of drugs known as benzodiazepines.

Dimethyl Fumarate

Generic Formulation: Dimethyl FumarateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
UT State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills33.1
Peer Average Days Supply985
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.3% less volume than the regional standard for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,170.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$470.01

State Avg Cost Per Claim

$1,002.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fumarate derivative that is used as a DERMATOLOGIC AGENT in the treatment of PSORIASIS and SKIN DISEASES. It also may be used as an IMMUNOSUPPRESSIVE AGENT in the treatment of MULTIPLE SCLEROSIS.

Therapeutic Applications

Dimethyl fumarate is used to treat multiple sclerosis (MS). It is not a cure for MS. It helps decrease the number of episodes of worsening MS.

Gabapentin

Generic Formulation: GabapentinSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 61
30-Day Fills 100.7
Days Supply 3,010
UT State Average Benchmarks
Peer Average Claims77.0
Peer Average 30-Day Fills130.5
Peer Average Days Supply3,829
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,163.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.47

State Avg Cost Per Claim

$26.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Nurtec Odt

Generic Formulation: Rimegepant SulfateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 372
UT State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.5
Peer Average Days Supply575
Conservative Utilization

This provider writes prescriptions for this formulation 48.0% less frequently than the standard regional baseline metric for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,300.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$946.22

State Avg Cost Per Claim

$1,098.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent or treat migraine. Rimegepant may work by changing the amount of a certain natural substance in the brain. It helps to relieve headache, pain, and other migraine symptoms (such as nausea, vomiting, sensitivity to light/sound). Prompt treatment helps you return to your normal routine and may decrease your need for other pain medications.

Pregabalin

Generic Formulation: PregabalinSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 20
30-Day Fills 32.0
Days Supply 958
UT State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills48.1
Peer Average Days Supply1,409
Conservative Utilization

This provider writes prescriptions for this formulation 45.9% less frequently than the standard regional baseline metric for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $524.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.23

State Avg Cost Per Claim

$39.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.

Therapeutic Applications

This medication is used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, or spinal cord injury. This medication is also used to treat pain in people with fibromyalgia. It is also used with other medications to treat certain types of seizures (focal seizures).

Tecfidera

Generic Formulation: Dimethyl FumarateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
UT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.5
Peer Average Days Supply851
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $181,771.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,088.57

State Avg Cost Per Claim

$9,256.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fumarate derivative that is used as a DERMATOLOGIC AGENT in the treatment of PSORIASIS and SKIN DISEASES. It also may be used as an IMMUNOSUPPRESSIVE AGENT in the treatment of MULTIPLE SCLEROSIS.

Therapeutic Applications

Dimethyl fumarate is used to treat multiple sclerosis (MS). It is not a cure for MS. It helps decrease the number of episodes of worsening MS.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ELIZABETH EVE POTTER provides transparency into local medical care patterns within Salt Lake City, UT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.